文献速递其他结缔组织病

基于初始血清生物标志物组合的皮肌炎/多发性肌炎相关间质性肺病死亡风险预测模型

Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease.
PubMed 文献 · Arthritis Rheumatol · 2021-02-22

本研究利用日本多中心回顾性队列(497例推导队列,111例验证队列)建立PM/DM-ILD死亡预测模型。抗MDA-5抗体状态、CRP和KL-6水平被确定为独立危险因素,据此构建的MCK模型可将患者分为低(<15%)、中(15-50%)、高(≥50%)死亡风险组,并在验证队列中重现。

要点

  • 抗MDA-5抗体、CRP和KL-6是PM/DM-ILD死亡的独立危险因素。
  • MCK模型基于上述三个因素将死亡风险分为低、中、高三层。
  • MCK模型在抗MDA-5阳性及阴性患者中均能区分累积生存率。

核心结论

  • 基于CRP、KL-6水平联合抗MDA-5抗体状态的循证风险预测模型可能有助于预测PM/DM-ILD患者的预后。

研究设计与样本

  • 多中心回顾性队列研究,使用日本肌炎相关ILD患者数据库(JAMI)的497例新发PM/DM-ILD病例作为推导队列,另收集111例作为验证队列。

主要发现

  • 在推导队列中,CRP和KL-6水平在抗MDA-5阳性及阴性患者中均为死亡的独立危险因素。
  • 基于抗MDA-5抗体状态、CRP水平和KL-6水平构建的MCK模型将患者分为低(<15%)、中(15-50%)、高(≥50%)死亡风险组。
  • MCK模型在抗MDA-5阳性患者中成功区分累积生存率(低 vs 中风险 P < 0.01;中 vs 高风险 P = 0.03)。
  • MCK模型在抗MDA-5阴性患者中成功区分累积生存率(低 vs 中风险 P < 0.001)。
  • MCK模型的效用在意验证队列中得到了重现。

关键数值与推荐

  • MCK模型风险分层:低风险(<15%)、中风险(15-50%)、高风险(≥50%)。
  • 抗MDA-5阳性患者累积生存率比较:低 vs 中风险 P < 0.01,中 vs 高风险 P = 0.03。
  • 抗MDA-5阴性患者累积生存率比较:低 vs 中风险 P < 0.001。

临床怎么用

  • 对于PM/DM-ILD患者,可检测初始血清CRP、KL-6水平及抗MDA-5抗体状态,使用MCK模型进行死亡风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To establish predictive models for mortality in patients with polymyositis/dermatomyositis-associated interstitial lung disease (PM/DM-ILD) using a combination of initial serum biomarker levels. METHODS: The Multicenter Retrospective Cohort of Japanese Patients with Myositis-Associated ILD (JAMI) database of 497 incident cases of PM/DM-ILD was used as a derivation cohort, and 111 cases were additionally collected as a validation cohort. Risk factors predictive of all-cause mortality were identified by univariate and multivariable Cox regression analyses using candidate serum biomarkers as explanatory variables. The predictive models for mortality were generated in patients with and those without anti-melanoma differentiation-associated gene 5 (MDA-5) antibody, using a combination of risk factors. Cumulative survival rates were assessed using Kaplan-Meier analysis, and were compared between subgroups using the Breslow test. RESULTS: In the derivation cohort, C-reactive protein (CRP) and Krebs von den Lungen 6 (KL-6) levels were identified as independent risk factors for mortality in both anti-MDA-5-positive and anti-MDA-5-negative patients. We then developed a prediction model based on anti-MDA-5 antibody status, CRP level, and KL-6 level, termed the "MCK model," to identify patients at low (<15%), moderate (15-50%), or high (≥50%) risk of mortality, based on the number of risk factors. The MCK model successfully differentiated cumulative survival rates in anti-MDA-5-positive patients (P < 0.01 for low versus moderate risk and P = 0.03 for moderate versus high risk) and in anti-MDA-5-negative patients (P < 0.001 for low versus moderate risk). The utility of the MCK model was replicated in the validation cohort. CONCLUSION: Our findings indicate that an evidence-based risk prediction model using CRP and KL-6 levels combined with anti-MDA-5 antibody status might be useful for predicting prognosis in patients with PM/DM-ILD.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Gono T, Masui K, Nishina N, et al. Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2021. PMID: 33118321. doi:10.1002/art.41566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。